ACAAI: Epinephrine Auto-Injector Use Low Among Adults With Food Allergy
MONDAY, Nov. 14, 2022 (HealthDay News) — Only half of adults with food allergies have immediate access to epinephrine auto-injectors (EAIs), according to a study presented at the annual meeting of the American College of Allergy, Asthma & Immunology,…
Learn MoreAcupuncture Reduces Aromatase Inhibitor-Related Joint Pain
MONDAY, Nov. 14, 2022 (HealthDay News) — Among women with early breast cancer who have aromatase inhibitor-related joint pain, pain at 52 weeks is reduced with true acupuncture (TA) compared with sham acupuncture (SA) or waiting-list control (WC), ac…
Learn MoreBepirovirsen Studied for Treatment of Chronic Hepatitis B Infection
MONDAY, Nov. 14, 2022 (HealthDay News) — A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9 to 10 percent of patients with chronic HBV infection, acco…
Learn MoreDangerous Myths Keep Many Adults With Food Allergies From Getting an EpiPen
MONDAY, Nov. 14, 2022 (HealthDay News) — The EpiPen is a known lifesaver when someone with a serious food allergy eats something they can’t tolerate.Yet the auto-injection treatment is greatly underused in the United States, according to a new survey…
Learn MoreRaise Med Dosages in Weeks After Heart Failure Crisis for Better Outcome: Study
THURSDAY, Nov. 10, 2022 (HealthDay News) — When people with heart failure wind up in the hospital, it tends to become a slippery slope: They are more likely to be readmitted or die within six months during this vulnerable period.Now, new research sho…
Learn MoreAntiepileptic Med Use Increasing in Nursing Home Residents With Dementia
THURSDAY, Nov. 10, 2022 (HealthDay News) — Antiepileptic prescribing among nursing home residents with Alzheimer disease and related dementias (ADRD) is increasing, according to a study published online Nov. 9 in the Journal of the American Geriatric…
Learn MoreNab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
THURSDAY, Nov. 10, 2022 (HealthDay News) — For patients with platinum-refractory or cisplatin-ineligible advanced urothelial cancer, the combination of nab-paclitaxel and pembrolizumab is promising, according to a study published online Nov. 1 in The…
Learn MoreUn estudio compara dos diuréticos comunes que se usan para la insuficiencia cardiaca
MARTES, 8 de noviembre de 2022 (HealthDay News) — Los pacientes con insuficiencia cardiaca con frecuencia reciben una receta de un diurético para prevenir la acumulación de fluidos. Un nuevo estudio encontró que dos medicamentos que se recetan con fr…
Learn MoreASN: Empagliflozin Cuts Risk for Progression in CKD
WEDNESDAY, Nov. 9, 2022 (HealthDay News) — For patients with chronic kidney disease at risk for progression, the risk for progression of kidney disease or death from cardiovascular causes is reduced with empagliflozin treatment, according to a study …
Learn MoreASN: Discontinuation of RAS Inhibitors Does Not Increase eGFR in CKD
WEDNESDAY, Nov. 9, 2022 (HealthDay News) — For patients with advanced and progressive chronic kidney disease, discontinuation of treatment with renin-angiotensin system (RAS) inhibitors is not associated with a difference in the long-term rate of dec…
Learn More